World Journal of Advanced Research and Reviews
eISSN: 2581-9615 CODEN (USA): WJARAI
Cross Ref DOI: 10.30574/wjarr
Journal homepage: https://wjarr.com/

(RESEARCH ARTICLE)

Gut microbiota and immune tolerance mechanisms in autoimmune diseases

Farzana Hossaini *

Translational Immunology and Immunotherapy, Institute for Biomedical Sciences, Georgia State University, USA.

World Journal of Advanced Research and Reviews, 2025, 28(02), 2649–2666

Publication history: Received on 03 October 2025; revised on 22 November 2025; accepted on 29 November 2025

Article DOI: https://doi.org/10.30574/wjarr.2025.28.2.3812

Abstract

Autoimmune diseases arise from a failure of immune tolerance, leading to chronic immune-mediated damage to self-tissues. Increasing evidence indicates that the gut microbiota plays a central role in shaping immune development, maintaining immune homeostasis, and regulating tolerance mechanisms. This review synthesizes current knowledge on the interactions between gut microbial communities and the host immune system in the context of autoimmune pathogenesis. Special emphasis is placed on regulatory T cell (Treg) induction, short-chain fatty acid (SCFA) signaling, intestinal barrier integrity, and antigen-presenting cell modulation as key mechanisms through which the microbiota maintains immune tolerance. Dysbiosis has been consistently associated with autoimmune conditions such as rheumatoid arthritis, type 1 diabetes, multiple sclerosis, and inflammatory bowel disease, suggesting that microbial imbalance contributes to disease onset and progression. Furthermore, emerging evidence highlights the therapeutic potential of microbiota-targeted interventions, including dietary modulation, probiotics, and defined microbial consortia, in restoring immune equilibrium. Integrating findings from immunology and microbiome research, this paper underscores the gut microbiota as a dynamic regulator of immune tolerance and a promising target for precision medicine approaches in autoimmune diseases. Understanding these mechanisms provides critical insights for developing novel diagnostic and therapeutic strategies aimed at preventing and managing immune-mediated disorders.

Keywords: Gut Microbiota; Immune Tolerance; Autoimmune Diseases; Dysbiosis; Regulatory T Cells; Short-Chain Fatty Acids; Intestinal Barrier; Immunomodulation; Microbiome Therapy; Inflammation.

1. Introduction

1.1. Autoimmune Diseases as a Global Health Challenge

Autoimmune diseases represent a heterogeneous group of chronic inflammatory disorders characterized by a fundamental failure of immune tolerance, leading to persistent immune-mediated damage against self-tissues. These conditions affect multiple organ systems and include clinically significant diseases such as rheumatoid arthritis, type 1 diabetes mellitus, multiple sclerosis, and inflammatory bowel disease. Although genetic susceptibility plays an important role in disease predisposition, it is increasingly evident that environmental exposures, microbial interactions, and immune system dysregulation collectively shape disease onset and progression. In particular, host–microbiota interactions have emerged as a central explanatory framework for understanding the rising prevalence and complexity of autoimmune conditions in modern populations, where shifts in lifestyle, diet, and microbial exposure may contribute to immune imbalance and chronic inflammation (Macpherson & Harris, 2004; Honda & Littman, 2016; Zheng et al., 2020).

---

* Corresponding author: Farzana Hossaini

1.2. Immune Tolerance: Central Concept in Autoimmunity

Immune tolerance refers to the tightly regulated ability of the immune system to distinguish self-antigens from non-self antigens and to prevent inappropriate immune activation against host tissues. This process is maintained through both central tolerance mechanisms, which eliminate autoreactive immune cells during development, and peripheral tolerance mechanisms, which suppress or regulate self-reactive immune responses in mature immune compartments. Breakdown of these mechanisms is a defining feature of autoimmune pathology. Regulatory T cells (Tregs) play a critical role in maintaining immune equilibrium by suppressing effector T cell responses and controlling inflammatory cascades. In addition, cytokine networks such as IL-10 and transforming growth factor-beta (TGF-β), along with antigen-presenting cell regulation, are essential components that ensure immune homeostasis and prevent pathological autoimmunity (Honda & Littman, 2016; Belkaid & Hand, 2014; Kamada et al., 2013).

1.3. Gut Microbiota as an Immunological Organ

The gut microbiota is now widely recognized as a functional immunological organ due to its continuous bidirectional interaction with the host immune system. This complex microbial ecosystem contributes to immune system maturation during early life and maintains immune homeostasis throughout adulthood. It influences both innate and adaptive immune responses through microbial-associated molecular patterns (MAMPs), metabolic products, and direct interaction with intestinal immune cells. The gut-associated lymphoid tissue (GALT) serves as a major site of immune education, where microbial antigens are sampled and processed to shape immune tolerance and responsiveness. Importantly, commensal microorganisms actively participate in balancing inflammatory and anti-inflammatory pathways, thereby regulating systemic immune tone and preventing excessive immune activation (Belkaid & Hand, 2014; Brown et al., 2013; Thaiss et al., 2016).

1.4. Dysbiosis and Autoimmune Disease Association

Dysbiosis, defined as a disruption in the composition, diversity, and functional capacity of the gut microbiota, has been consistently associated with the development and progression of autoimmune diseases. Emerging metagenomic and clinical evidence suggests that microbial imbalance is not merely a consequence but may actively contribute to immune dysregulation and disease pathogenesis. In inflammatory bowel disease, distinct microbial signatures are observed, characterized by reduced diversity and altered community structure. Similarly, rheumatoid arthritis has been linked to specific microbial shifts, including enrichment of pro-inflammatory taxa, while type 1 diabetes is associated with early-life microbial alterations that precede clinical disease onset. These findings collectively support the hypothesis that dysbiosis can influence immune tolerance mechanisms and trigger aberrant immune activation in genetically susceptible individuals (Frank et al., 2007; Peterson et al., 2008; Levy et al., 2017; Vatanen et al., 2018).

1.5. Rationale and Aim of the Review

Given the growing evidence linking gut microbiota to immune regulation and autoimmune disease pathogenesis, there is a critical need to synthesize current knowledge into a unified mechanistic framework. This review aims to systematically examine how gut microbiota regulates immune tolerance mechanisms and how disruptions in this system contribute to autoimmune disease development. It further explores the interplay between microbial composition, metabolic signaling, epithelial barrier integrity, and immune cell modulation. By integrating insights from immunology, microbiome science, and metabolic research, this work seeks to provide a comprehensive understanding of the gut–immune axis and its implications for therapeutic intervention and disease prevention strategies (Rooks & Garrett, 2016; Zheng et al., 2020).



Figure 1 The Gut Microbiota–Immune System Axis in Immune Homeostasis and Autoimmunity

This figure presents a conceptual framework illustrating the bidirectional interaction between gut microbiota and the host immune system. It highlights how microbial communities within the gastrointestinal tract communicate with gut-associated lymphoid tissue (GALT), including Peyer's patches and lamina propria, to regulate immune development and function. Innate immune cells such as dendritic cells and macrophages act as primary sensors of microbial signals, initiating downstream immune responses that shape adaptive immunity.

The diagram further demonstrates how microbiota-driven signaling influences key adaptive immune components, including regulatory T cells (Tregs), T helper 17 (Th17) cells, and B cells, which collectively determine the balance between immune tolerance and inflammatory activation. Under homeostatic conditions, microbial interactions promote immune tolerance and maintain intestinal equilibrium. However, dysbiosis disrupts these interactions, shifting immune responses toward pro-inflammatory pathways that contribute to the development of autoimmune diseases.

Overall, this figure serves as a foundational model for understanding the gut microbiota–immune axis and its central role in maintaining immune homeostasis versus driving autoimmune pathology.

2. Gut Microbiota–Immune System Crosstalk

2.1. Gut-Associated Lymphoid Tissue (GALT) and Immune Education

The gut-associated lymphoid tissue (GALT) represents one of the most extensive and immunologically active compartments of the human immune system, functioning as a primary interface between the host and the intestinal microbiota. It includes specialized structures such as Peyer's patches, isolated lymphoid follicles, mesenteric lymph nodes, and the lamina propria, all of which collectively contribute to immune surveillance and immune education. Continuous exposure to commensal microbial antigens within this environment is essential for the development of immune competence and tolerance. Rather than triggering pathogenic inflammation, controlled antigen sampling by epithelial cells and microfold (M) cells facilitates a calibrated immune response that promotes symbiosis between host and microbiota. This process enables immune cells to distinguish between harmless commensals and harmful pathogens, thereby preventing unnecessary immune activation while maintaining defensive capacity. In this context, GALT acts as a dynamic training ground where naïve immune cells are conditioned toward regulatory or effector phenotypes depending on microbial cues and environmental context, establishing long-term immune homeostasis (Brown et al., 2013; Macpherson & Harris, 2004).

2.2. Innate Immune Recognition of Microbial Signals

Innate immune recognition represents the first line of host defense and plays a crucial role in interpreting microbial signals from the gut microbiota. This process is mediated primarily through pattern recognition receptors (PRRs), including Toll-like receptors (TLRs), NOD-like receptors (NLRs), and other cytosolic sensors that detect conserved microbial-associated molecular patterns. Activation of these receptors initiates downstream signaling cascades that regulate cytokine production, antimicrobial peptide secretion, and inflammatory responses. Importantly, the interaction between PRRs and commensal microbiota is not solely pro-inflammatory; instead, it is highly context-dependent and contributes to immune calibration and tolerance under physiological conditions. Controlled PRR signaling supports epithelial integrity and immune equilibrium, whereas excessive or dysregulated activation can lead to chronic inflammation and autoimmune pathology. The balance between microbial stimulation and host immune restraint is therefore essential in maintaining intestinal and systemic immune homeostasis. Disruption of this equilibrium has been implicated in a range of inflammatory and autoimmune disorders, highlighting the importance of finely tuned innate immune–microbiota interactions in disease prevention (Kamada et al., 2013; Thaiss et al., 2016; Littman & Pamer, 2011).

2.3. Adaptive Immune Regulation by Microbiota

The gut microbiota plays a fundamental role in shaping adaptive immune responses by influencing the differentiation, function, and distribution of key immune cell populations. Microbial signals regulate the development of T helper cell subsets, including pro-inflammatory Th17 cells and anti-inflammatory regulatory T cells, thereby determining the overall inflammatory tone of the immune system. In parallel, gut-resident microbes contribute to the maturation and activation of B cells, promoting class switching and the production of immunoglobulin A (IgA), which is essential for mucosal immunity and microbial containment. This IgA-mediated response forms a critical feedback loop that limits microbial translocation while preserving beneficial microbial communities. Additionally, microbial metabolites and antigenic stimulation from commensals contribute to the functional programming of adaptive immune cells, ensuring that immune responses remain appropriately balanced between tolerance and defense.



Figure 2 Gut Microbiota–Immune Crosstalk via Innate and Adaptive Immunity

Collectively, these processes highlight the central role of the gut microbiota in orchestrating adaptive immune regulation and maintaining systemic immune equilibrium, with significant implications for autoimmune disease development when these interactions are disrupted (Honda & Littman, 2016; Brown et al., 2013).

Figure 2 illustrates the mechanistic interaction between the gut microbiota and the host immune system, highlighting how microbial signals are integrated through both innate and adaptive immune pathways to maintain immune homeostasis or drive immune dysregulation. At the innate immune level, microbial-associated molecular patterns are recognized by pattern recognition receptors (PRRs), including Toll-like receptors (TLRs) and NOD-like receptors (NLRs), which initiate downstream signaling cascades that regulate cytokine production, inflammation, and epithelial defense responses. These early signaling events determine whether the immune system adopts a tolerogenic or pro-inflammatory state.

Following innate immune activation, dendritic cells function as key antigen-presenting cells that process microbial antigens and present them to naïve T cells, thereby shaping adaptive immune responses. Depending on the nature of microbial cues, dendritic cells promote differentiation into either regulatory T cells (Tregs), which support immune tolerance, or effector T cells such as Th17 cells, which contribute to inflammatory responses. This balance is critical in determining immune outcomes and susceptibility to autoimmune disease.

In parallel, gut microbiota also influences B cell maturation and promotes immunoglobulin A (IgA) production, which plays a central role in mucosal immunity by limiting microbial translocation and maintaining microbial homeostasis. Collectively, these interconnected pathways demonstrate how the gut microbiota orchestrates a finely tuned immune network that integrates innate sensing, antigen presentation, T cell differentiation, and mucosal antibody responses to maintain immune equilibrium or, when dysregulated, contribute to autoimmune pathology.

---

3. Mechanisms of Immune Tolerance Induced by Gut Microbiota

3.1. Regulatory T Cell (Treg) Induction

One of the most critical mechanisms through which the gut microbiota maintains immune tolerance is the induction and expansion of regulatory T cells (Tregs), particularly FoxP3+ Tregs. These cells play a central role in suppressing excessive immune activation and maintaining immune homeostasis within both intestinal and systemic compartments. Specific microbial taxa, especially members of *Clostridia* clusters, have been shown to strongly promote the differentiation of colonic Tregs through antigen-dependent and metabolite-mediated pathways. These bacteria create a microenvironment that favors anti-inflammatory signaling and enhances Treg accumulation in the colonic lamina propria. The resulting increase in Treg populations leads to elevated production of immunosuppressive cytokines such as IL-10 and TGF-β, which collectively suppress effector T cell responses and prevent autoimmune activation. This microbiota-driven immune programming represents a fundamental pathway linking commensal bacteria to long-term immune tolerance and protection against inflammatory disease states (Atarashi et al., 2013; Arpaia et al., 2013).

3.2. Microbial Metabolites and Short-Chain Fatty Acids (SCFAs)

Microbial metabolites, particularly short-chain fatty acids (SCFAs) such as butyrate, acetate, and propionate, serve as key signaling molecules in the regulation of immune tolerance. These metabolites are primarily produced through the fermentation of dietary fibers by gut commensals and exert wide-ranging immunomodulatory effects on host immune cells. Butyrate, in particular, has been shown to promote the differentiation of regulatory T cells by enhancing histone acetylation at the FoxP3 gene locus, thereby facilitating transcriptional activation of tolerance-associated pathways. SCFAs also influence dendritic cell function and reduce the production of pro-inflammatory cytokines, further reinforcing immune homeostasis. In addition to their direct immunological effects, SCFAs contribute to epithelial health and energy metabolism, thereby creating an environment conducive to immune balance. Collectively, these microbial metabolites act as essential mediators connecting diet, microbiota composition, and immune regulation, highlighting their central role in preventing immune dysregulation and autoimmunity (Furusawa et al., 2013; Rooks & Garrett, 2016).

3.3. Intestinal Barrier Integrity and Permeability Regulation

The intestinal epithelial barrier serves as a critical physical and immunological interface between the host and the gut microbiota. A healthy microbiota plays an essential role in maintaining the integrity of this barrier by regulating tight junction proteins, epithelial regeneration, and mucosal defense mechanisms. When microbial balance is disrupted, intestinal permeability increases, a condition often referred to as “leaky gut,” which allows microbial components such as lipopolysaccharides (LPS) and other antigens to translocate into systemic circulation. This translocation triggers systemic immune activation and contributes to chronic inflammation, which is a key feature of autoimmune disease pathogenesis. Evidence suggests that dysbiosis-induced barrier dysfunction is closely associated with inflammatory and metabolic disorders, reinforcing the importance of microbial homeostasis in maintaining epithelial integrity. Thus, gut microbiota–driven regulation of barrier function represents a fundamental checkpoint in preventing immune overactivation and systemic autoimmunity (Takiishi et al., 2017; Thaiss et al., 2018).

3.4. Dendritic Cell Modulation and Immune Tolerance

Dendritic cells (DCs) act as pivotal antigen-presenting cells that determine whether immune responses result in tolerance or inflammation. The gut microbiota plays a significant role in shaping dendritic cell phenotype and function, promoting a tolerogenic state that favors immune suppression rather than activation. Commensal-derived signals condition dendritic cells to produce anti-inflammatory cytokines such as IL-10 while reducing pro-inflammatory cytokine secretion. These tolerogenic dendritic cells are essential for the induction of regulatory T cells and the suppression of autoreactive T cell responses. In contrast, dysbiosis can disrupt dendritic cell programming, leading to exaggerated immune activation and loss of tolerance. This balance between microbial signals and dendritic cell responses is therefore a central mechanism through which the gut microbiota regulates systemic immune homeostasis and prevents autoimmune inflammation (Kamada et al., 2013; Macpherson & Harris, 2004).

3.5. Secretory IgA and Mucosal Immune Regulation

Secretory immunoglobulin A (IgA) is a key effector molecule of mucosal immunity that plays an essential role in maintaining microbial balance and preventing excessive immune activation. Produced by plasma cells in the intestinal lamina propria, IgA is secreted into the gut lumen where it binds to microbial antigens and limits bacterial adherence to epithelial surfaces. This process prevents microbial translocation and maintains spatial segregation between commensals and host tissues. Importantly, IgA does not typically trigger inflammatory responses, making it a critical component of non-inflammatory immune defense.



Figure 3 Mechanisms of Microbiota-Induced Immune Tolerance

By regulating microbial composition and limiting antigen exposure, IgA contributes to immune homeostasis and reduces the risk of aberrant immune activation. Disruption of IgA-mediated regulation can lead to microbial imbalance and increased susceptibility to inflammatory and autoimmune conditions. Thus, secretory IgA serves as a key immunological barrier that supports long-term immune tolerance in the gut environment (Brown et al., 2013; Littman & Pamer, 2011).

Figure 3 presents a comprehensive mechanistic overview of how the gut microbiota contributes to the establishment and maintenance of immune tolerance. The figure illustrates multiple interconnected pathways through which commensal microorganisms regulate host immune homeostasis and suppress excessive inflammatory responses.

The schematic begins with the fermentation of dietary fibers by commensal bacteria, leading to the production of short-chain fatty acids (SCFAs), including butyrate, acetate, and propionate. These metabolites serve as key immunomodulatory molecules that promote regulatory immune functions. SCFAs enhance the differentiation and expansion of FoxP3+ regulatory T cells (Tregs), which play a central role in suppressing autoreactive immune responses and maintaining peripheral immune tolerance.

The figure further demonstrates the epigenetic mechanisms underlying microbiota-mediated immune regulation. In particular, butyrate-mediated inhibition of histone deacetylases (HDACs) promotes histone acetylation and activates tolerance-associated gene expression, including genes involved in Treg differentiation and anti-inflammatory cytokine production.

Another major component illustrated is intestinal barrier integrity. The gut microbiota strengthens epithelial tight junction proteins such as occludin, claudin, and ZO-1, thereby preventing microbial translocation and systemic immune activation. Maintenance of barrier function is essential for protecting against chronic inflammation and autoimmune disease development.

Additionally, the figure highlights IgA-mediated microbial control, where commensal bacteria stimulate B cell maturation and secretory IgA production. IgA helps maintain microbial balance by limiting bacterial adhesion and penetration into epithelial tissues, thereby supporting mucosal immune homeostasis.

Overall, the figure integrates metabolic, cellular, epigenetic, and mucosal immune pathways into a unified framework demonstrating how gut microbiota orchestrates immune tolerance and protects against autoimmune pathology.

4. Gut Dysbiosis in Autoimmune Diseases

4.1. Rheumatoid Arthritis (RA)

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by persistent synovial inflammation, joint destruction, and systemic immune dysregulation. Increasing evidence indicates that gut microbial dysbiosis plays a contributory role in RA pathogenesis by altering immune homeostasis and promoting systemic inflammation. Patients with RA often exhibit reduced microbial diversity along with enrichment of pro-inflammatory bacterial taxa and depletion of beneficial commensals. These microbial alterations are believed to influence immune cell activation, particularly enhancing Th17-mediated inflammatory responses while suppressing regulatory immune pathways. Moreover, studies have demonstrated that microbial composition in RA patients may partially normalize following treatment, suggesting a dynamic relationship between disease activity and gut microbiota composition. Collectively, these findings support the hypothesis that gut microbiota imbalance contributes to immune dysregulation and may act as both a biomarker and a potential therapeutic target in RA (Scher & Abramson, 2011; Zhang et al., 2015).

Table 1 Gut Microbiota Alterations in Major Autoimmune Diseases

Disease	**Microbial Signature Changes**	**Immune Mechanism Affected**	**Key Outcomes**
Rheumatoid Arthritis (RA)	Increased abundance of pro-inflammatory taxa such as *Prevotella copri* and reduction of beneficial commensals	Enhanced Th17-mediated inflammation, reduced Treg activity, chronic cytokine activation	Synovial inflammation, joint destruction, systemic immune dysregulation
Type 1 Diabetes (T1D)	Reduced microbial diversity, altered early-life microbiome composition,	Breakdown of immune tolerance, activation of	Autoimmune destruction of pancreatic β-cells and insulin deficiency

	decreased SCFA-producing bacteria	autoreactive T cells, impaired epithelial barrier integrity	
Multiple Sclerosis (MS)	Dysbiosis associated with altered gut–brain axis signaling and reduced beneficial microbial metabolites	Neuroimmune dysregulation, increased CNS inflammatory responses, imbalance in Th17/Treg ratio	Demyelination, neuroinflammation, progressive neurological impairment
Inflammatory Bowel Disease (IBD)	Reduced microbial diversity, depletion of anti-inflammatory bacteria, expansion of pathogenic taxa	Exaggerated mucosal immune activation, impaired epithelial barrier function, chronic intestinal inflammation	Persistent intestinal inflammation, tissue damage, compromised gut homeostasis
Reactive Arthritis	Post-infectious microbial perturbations and altered gut microbial composition	Persistent immune activation, abnormal antigen presentation, inflammatory cytokine production	Joint inflammation following gastrointestinal or genitourinary infection
Post-Infectious Spondyloarthritis	Altered microbiome composition after enteric infection and decreased commensal stability	Dysregulated innate and adaptive immune responses, chronic inflammatory signaling	Chronic arthritis, systemic inflammation, autoimmune progression

This table comparatively summarizes the major gut microbiota alterations associated with key autoimmune diseases, highlighting disease-specific microbial signatures, affected immune pathways, and resulting pathological outcomes. It provides an integrated overview of how dysbiosis contributes to immune dysregulation and autoimmune disease progression.

4.2. Type 1 Diabetes (T1D)

Type 1 diabetes (T1D) is an autoimmune disorder characterized by immune-mediated destruction of pancreatic β-cells, leading to insulin deficiency. Emerging evidence suggests that early-life gut microbiome composition plays a critical role in shaping immune tolerance and susceptibility to T1D. Longitudinal studies indicate that microbial alterations often precede the clinical onset of disease, highlighting a potential causal relationship between dysbiosis and autoimmune activation. Reduced microbial diversity and shifts in key bacterial populations have been observed in individuals at high risk for T1D. These microbial changes are thought to influence immune development by modulating innate immune signaling, metabolic pathways, and T cell differentiation, thereby contributing to loss of tolerance against pancreatic antigens. Additionally, interactions between host genetics, environmental exposures, and microbial composition further amplify immune dysregulation in T1D pathogenesis (Vatanen et al., 2018; Wen et al., 2008; Burcelin et al., 2013).

4.3. Multiple Sclerosis (MS)

Multiple sclerosis (MS) is a chronic autoimmune neuroinflammatory disorder characterized by demyelination and neurodegeneration within the central nervous system. The gut microbiota has emerged as a key modulator of neuroimmune communication through the gut–brain axis, influencing both peripheral immune responses and central nervous system inflammation. Microbial metabolites and immune signaling molecules derived from gut bacteria can cross or indirectly influence the blood–brain barrier, thereby shaping neuroinflammatory processes. Dysbiosis in MS patients has been associated with altered immune cell profiles, including changes in regulatory T cell populations and pro-inflammatory T cell activity. These findings suggest that gut microbiota composition may play a significant role in regulating systemic immune responses that contribute to CNS inflammation and disease progression. The gut–brain axis therefore represents a critical pathway linking microbial imbalance to neuroimmune dysregulation in MS (Cryan et al., 2019; Zheng et al., 2020).

4.4. Inflammatory Bowel Disease (IBD)

Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, is strongly associated with profound alterations in gut microbial composition and mucosal immune dysfunction. Patients with IBD typically exhibit reduced microbial diversity, decreased abundance of beneficial commensals, and expansion of potentially pathogenic bacteria. These microbial shifts are closely linked to impaired epithelial barrier function and exaggerated immune responses within the intestinal mucosa. Metagenomic analyses have consistently demonstrated distinct microbial signatures in IBD patients compared to healthy individuals, supporting the role of dysbiosis in disease pathogenesis. The interaction between altered microbiota and dysregulated immune responses contributes to chronic intestinal inflammation and tissue damage, highlighting the central role of the gut ecosystem in maintaining mucosal immune balance (Frank et al., 2007; Peterson et al., 2008).

4.5. Reactive and Post-Infectious Arthritis

Reactive and post-infectious arthritis are inflammatory conditions that develop following bacterial or viral infections and are closely associated with alterations in gut microbial composition. These conditions are characterized by immune system hyperactivation triggered by microbial antigens, which may persist even after the resolution of the initial infection. Emerging evidence suggests that microbiome perturbations contribute to sustained immune dysregulation and chronic inflammatory responses in susceptible individuals. Changes in gut microbial communities may influence antigen presentation, cytokine production, and T cell activation, thereby perpetuating joint inflammation. The persistence of immune activation following infection highlights the role of the microbiome as a mediator between environmental triggers and host immune responses in post-infectious autoimmune conditions (Manasson et al., 2020).



Figure 4 Dysbiosis-Driven Pathways in Autoimmune Disease Development

This figure illustrates a stepwise mechanistic model linking gut microbiota dysregulation to the development and progression of autoimmune diseases. It begins with environmental triggers such as an unhealthy diet, infections, antibiotic exposure, and genetic or lifestyle susceptibility. These factors collectively disrupt the stability of the gut ecosystem, leading to microbiome imbalance (dysbiosis) characterized by reduced beneficial commensals, decreased microbial diversity, and expansion of pathobionts and pro-inflammatory taxa. A key downstream consequence of this imbalance is the reduction of short-chain fatty acid (SCFA)-producing bacteria, which are critical for intestinal and immune homeostasis.

As dysbiosis progresses, it induces intestinal barrier dysfunction, marked by disruption of tight junction proteins (e.g., occludin, claudins, ZO-1) and increased gut permeability ("leaky gut"). This enables translocation of microbial products such as lipopolysaccharides (LPS) and flagellin into systemic circulation, triggering dendritic cell activation and subsequent skewing of adaptive immunity toward a Th17-dominant pro-inflammatory response, while regulatory T-cell (Treg) function is diminished. The resulting immune imbalance drives chronic cytokine production (e.g., IL-17, IL-6, TNF-α), sustained inflammation, and loss of immune tolerance.

Ultimately, this cascade culminates in autoimmune disease outcomes, including tissue damage, chronic inflammation, and organ-specific dysfunction such as rheumatoid arthritis, type 1 diabetes, multiple sclerosis, and inflammatory bowel disease. The figure also highlights a self-amplifying loop in which inflammation further exacerbates dysbiosis and barrier breakdown, reinforcing a chronic cycle of immune dysregulation and disease progression.

5. Molecular and Immunological Pathways

5.1. Cytokine Networks and Immune Regulation

Cytokine signaling networks represent a central regulatory axis through which the gut microbiota influences immune tolerance and inflammatory balance. Among these, interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β) are particularly critical in mediating microbiota-induced immune suppression and maintaining immune homeostasis. IL-10 functions as a potent anti-inflammatory cytokine that inhibits the activation of macrophages and dendritic cells, thereby reducing pro-inflammatory cytokine production and limiting tissue damage. TGF-β plays an equally important role in promoting immune tolerance by supporting regulatory T cell differentiation and suppressing effector T cell activation. Microbial metabolites and commensal-derived signals enhance the production of these cytokines, reinforcing a tolerogenic immune environment within the gut and systemically. Disruption of these cytokine pathways has been strongly associated with the breakdown of immune tolerance and the development of autoimmune pathology, highlighting their essential role in microbiota-mediated immune regulation (Arpaia et al., 2013).

5.2. Th17/Treg Balance in Autoimmunity

The balance between T helper 17 (Th17) cells and regulatory T cells (Tregs) represents a critical immunological checkpoint in the regulation of autoimmunity. Th17 cells are primarily pro-inflammatory and contribute to tissue inflammation through the production of cytokines such as IL-17, whereas Tregs suppress excessive immune responses and maintain tolerance. The gut microbiota plays a fundamental role in regulating this balance by influencing T cell differentiation pathways through microbial antigens, metabolites, and host–microbe interactions. A shift toward Th17 dominance is commonly associated with autoimmune disease development, whereas enhanced Treg activity promotes immune suppression and protection against inflammation. This dynamic equilibrium is therefore essential for immune homeostasis, and disruption of microbiota composition can tilt this balance toward pathological inflammation, contributing to autoimmune disease progression (Honda & Littman, 2016).

5.3. Epigenetic Regulation by Microbial Metabolites

Microbial metabolites, particularly short-chain fatty acids (SCFAs), play a significant role in regulating immune function through epigenetic mechanisms. SCFAs such as butyrate act as histone deacetylase (HDAC) inhibitors, thereby modifying chromatin structure and influencing gene expression in immune cells. This epigenetic modulation enhances the transcription of genes associated with immune tolerance, including those involved in regulatory T cell differentiation and anti-inflammatory cytokine production. By altering the epigenetic landscape of immune cells, microbial metabolites provide a direct molecular link between gut microbiota composition and host immune regulation. These mechanisms highlight how environmental factors, such as diet and microbial ecology, can induce long-lasting changes in immune function, potentially influencing susceptibility to autoimmune diseases (Furusawa et al., 2013).

5.4. Innate Immune Signaling Pathways

Innate immune signaling pathways serve as the first molecular interface between the host immune system and the gut microbiota. Microbial components are recognized by pattern recognition receptors (PRRs), including Toll-like receptors (TLRs) and other cytosolic sensors, which activate downstream signaling cascades such as NF-κB. These pathways regulate the production of cytokines, chemokines, and antimicrobial peptides that shape the inflammatory or tolerogenic outcome of immune responses. Under homeostatic conditions, commensal-derived signals promote balanced PRR activation that supports immune tolerance and epithelial integrity. However, dysregulated or excessive activation of these pathways can lead to chronic inflammation and autoimmune pathology. The ability of the microbiota to modulate innate immune signaling highlights its central role in maintaining immune equilibrium and preventing aberrant inflammatory responses (Thaiss et al., 2016).

Table 2 Molecular and Immunological Pathways Regulated by Gut Microbiota

Pathway	Key molecules	Immune effect	Clinical relevance
Cytokine signaling	IL-10, TGF-β	Promotes anti-inflammatory responses and immune tolerance; suppresses excessive immune activation	Reduced activity is linked to chronic inflammation and autoimmune susceptibility
Th17/Treg balance	IL-17, IL-6, FoxP3, TGF-β	Regulates immune homeostasis by balancing pro-inflammatory Th17 cells and regulatory T cells	Imbalance drives autoimmune conditions such as RA, MS, and IBD
SCFA epigenetics	Butyrate, acetate, propionate; histone deacetylases (HDACs)	Enhances Treg differentiation, strengthens epithelial barrier, and modulates gene expression via epigenetic regulation	Protective against metabolic and autoimmune diseases; loss associated with dysbiosis
NF-κB signaling	NF-κB, IκB, TNF-α, IL-1β	Central inflammatory pathway controlling cytokine production and innate immune activation	Chronic activation contributes to systemic inflammation and tissue damage in autoimmune disorders
PRR activation	Toll-like receptors (TLRs), NOD-like receptors (NLRs), LPS, flagellin	Initiates innate immune responses upon microbial recognition; can trigger downstream adaptive immune activation	Overactivation due to microbial translocation contributes to autoimmune pathogenesis

This table summarizes key molecular and immunological pathways influenced by gut microbiota and highlights their mechanistic roles in immune regulation and their clinical implications in autoimmune and inflammatory diseases.

6. Therapeutic Implications

6.1. Dietary Modulation and Prebiotics

Dietary intervention represents one of the most accessible and foundational strategies for modulating gut microbiota composition and restoring immune balance. Diets rich in complex carbohydrates and dietary fiber promote the growth of beneficial microbial communities that are capable of fermenting indigestible polysaccharides into short-chain fatty acids (SCFAs). These metabolites play a central role in regulating immune tolerance by enhancing regulatory T cell differentiation, strengthening epithelial barrier integrity, and reducing systemic inflammation. Conversely, diets low in fiber and high in processed foods are associated with reduced microbial diversity and increased susceptibility to dysbiosis, which may contribute to immune dysregulation and autoimmune disease progression. The interplay between dietary patterns, microbial ecology, and immune signaling underscores the importance of nutrition as a modifiable factor in immune-mediated disease prevention and management (Zhao et al., 2018; Sonnenburg & Bäckhed, 2016).

6.2. Probiotics and Defined Microbial Consortia

Probiotic therapy and the use of defined microbial consortia represent targeted approaches to restoring microbial balance and promoting immune tolerance. Probiotics, which consist of live beneficial microorganisms, can modulate gut microbial composition, enhance barrier function, and influence host immune responses. More advanced strategies involve the use of rationally designed microbial consortia that are selected for their ability to induce regulatory immune pathways, particularly regulatory T cell expansion. These engineered or selectively assembled microbial communities can more precisely restore immune homeostasis compared to single-strain probiotics. Experimental evidence suggests that such microbial interventions can suppress inflammatory responses and enhance immune regulation, offering promising therapeutic avenues for autoimmune diseases (Atarashi et al., 2013; Tanoue et al., 2019).

6.3. Microbiota-Based Immunotherapy

Microbiota-based immunotherapy is an emerging field that focuses on manipulating the gut microbial ecosystem to restore immune balance and treat immune-mediated diseases. This approach includes strategies such as microbiota transplantation, metabolite supplementation, and targeted microbial modulation to reshape host immune responses. By influencing the production of immunoregulatory metabolites and altering microbial community structure, these interventions aim to shift the immune system from a pro-inflammatory state toward immune tolerance. The growing understanding of microbiome–immune interactions has positioned microbiota-targeted therapies as a promising adjunct or alternative to conventional immunosuppressive treatments in autoimmune diseases. This paradigm reflects a shift toward ecosystem-based therapeutic strategies that target underlying immune dysregulation rather than merely controlling symptoms (Cani, 2018; Rooks & Garrett, 2016).

6.4. Precision Medicine and Data-Driven Microbiome Analysis

The integration of big data analytics, artificial intelligence (AI), and machine learning is transforming the study of microbiome–immune interactions into a data-driven discipline. Advanced computational models enable the identification of microbial signatures associated with autoimmune disease risk, progression, and therapeutic response. Machine learning algorithms can analyze complex multi-omics datasets, including metagenomics, metabolomics, and immunological profiles, to generate predictive models of immune dysregulation. These approaches facilitate precision medicine strategies by enabling personalized microbiome-based diagnostics and treatment planning. Additionally, AI-driven systems enhance the ability to detect subtle microbiome shifts that may precede clinical disease, providing opportunities for early intervention and prevention in autoimmune conditions (Chowdhury, 2024a, 2024b, 2024c; Zheng et al., 2020).

6.5. Digital and Secure Biomedical Systems

The increasing reliance on large-scale microbiome and biomedical datasets necessitates secure, scalable, and interoperable data management systems. Cloud-based data engineering frameworks enable efficient storage, processing, and analysis of complex microbiome datasets, supporting large-scale clinical and research applications. In parallel, blockchain technology offers enhanced data security, transparency, and integrity by ensuring tamper-proof records of biomedical data transactions. The integration of these digital technologies into microbiome research facilitates secure data sharing across institutions and improves reproducibility in scientific studies. Together, cloud computing and blockchain systems provide a robust infrastructure for advancing microbiome research and enabling trustworthy, scalable precision medicine applications in autoimmune disease research (Chowdhury et al., 2024d; Chowdhury, 2025).



Figure 5 Therapeutic Strategies Targeting Gut Microbiota in Autoimmune Diseases

Figure 5 presents a translational framework of therapeutic strategies targeting the gut microbiota for the prevention and management of autoimmune diseases. The figure highlights five major intervention layers: dietary modulation, probiotics and microbial consortia, fecal microbiota transplantation (FMT), AI-driven precision therapy, and blockchain-enabled data systems. Each strategy contributes to restoring microbial balance (eubiosis), strengthening intestinal barrier integrity, and improving immune homeostasis.

Dietary interventions rich in fiber and prebiotics enhance the growth of beneficial microbes and increase short-chain fatty acid (SCFA) production, which promotes anti-inflammatory immune responses. Probiotics and microbial consortia help restore microbial diversity, suppress pathogenic taxa, and reinforce gut barrier function. FMT represents a more direct microbial restoration approach by rebuilding disrupted microbial ecosystems and improving metabolic and immune regulation. Emerging AI-driven precision therapies integrate multi-omics and predictive analytics to personalize microbiome-based treatments and optimize therapeutic efficacy. In parallel, blockchain-enabled data systems support secure, transparent, and interoperable clinical data management, facilitating patient-centered precision medicine.

Collectively, these interventions aim to reduce inflammation, restore immune balance, improve gut barrier integrity, decrease medication dependence, and enhance long-term clinical outcomes. The figure emphasizes the growing integration of microbiome science, artificial intelligence, and digital health technologies in the development of next-generation therapies for autoimmune diseases.

7. Challenges and Research Gaps

Despite significant advancements in understanding the role of gut microbiota in immune tolerance and autoimmune disease pathogenesis, several critical challenges and unresolved research gaps remain that limit translation into clinical applications.

7.1. Lack of Causal Inference in Microbiome–Autoimmunity Relationships

A major limitation in current microbiome research is the predominance of associative rather than causal evidence linking gut microbial alterations to autoimmune disease development. While numerous studies demonstrate strong correlations between dysbiosis and diseases such as rheumatoid arthritis, type 1 diabetes, and inflammatory bowel disease, establishing direct causality remains methodologically challenging. This is largely due to the complexity of host–microbe interactions, confounding environmental variables, and the difficulty of replicating human immune systems in experimental models. As a result, it remains unclear whether microbial dysbiosis is a driving factor in disease initiation or a secondary consequence of ongoing inflammation and immune dysregulation (Levy et al., 2017).

7.2. Inter-Individual Variability in Microbiome Composition

The human gut microbiome exhibits substantial inter-individual variability influenced by genetics, diet, environment, geography, and lifestyle factors. This variability complicates the identification of universal microbial signatures associated with autoimmune diseases. Even among patients with the same disease phenotype, microbial compositions can differ significantly, making it difficult to define consistent biomarkers or therapeutic targets. This heterogeneity also limits the generalizability of microbiome-based interventions and highlights the need for personalized approaches in microbiome research and treatment strategies (Zheng et al., 2020).

7.3. Limited Longitudinal Cohort Studies

Most existing studies in microbiome–autoimmunity research are cross-sectional in nature, providing only a snapshot of microbial composition at a single time point. This significantly limits the ability to understand temporal dynamics and disease progression. Longitudinal cohort studies are essential to determine how microbial communities evolve before, during, and after the onset of autoimmune diseases. Although some early-life cohort studies have provided valuable insights, such as in type 1 diabetes research, large-scale longitudinal data across multiple autoimmune conditions remain limited. This gap restricts the ability to identify predictive microbial markers and early intervention opportunities (Vatanen et al., 2018).

7.4. Standardization Issues in Metagenomic Analysis Pipelines

Another major challenge in microbiome research is the lack of standardized methodologies for sample collection, sequencing, data processing, and analysis. Variability in metagenomic pipelines can lead to inconsistent results across studies, making comparisons difficult and limiting reproducibility. Differences in sequencing platforms, bioinformatic tools, and reference databases further contribute to discrepancies in microbial profiling. These methodological inconsistencies hinder the development of robust, clinically applicable microbiome-based diagnostics and therapeutic strategies. Establishing standardized analytical frameworks is therefore essential for advancing the reliability and translational potential of microbiome research (Cani, 2018).

8. Future Research Directions

8.1. Multi-Omics Integration (Metagenomics, Metabolomics, and Immunomics)

Future advancements in understanding gut microbiota–immune interactions will rely heavily on multi-omics integration approaches that combine metagenomics, metabolomics, transcriptomics, and immunomics data. This integrative framework enables a more comprehensive characterization of host–microbe interactions by linking microbial composition with functional metabolic outputs and host immune responses. Unlike single-layer analyses, multi-omics approaches allow researchers to identify mechanistic pathways rather than purely descriptive associations, thereby improving the understanding of how microbial metabolites influence immune tolerance and autoimmune disease progression. This systems-level perspective is expected to significantly enhance biomarker discovery and therapeutic target identification in autoimmune diseases.

8.2. AI-Based Immune Prediction Systems

The application of artificial intelligence (AI) and machine learning in microbiome research represents a transformative direction for predictive immunology. AI-based models can process large-scale, high-dimensional datasets to identify complex patterns within microbiome–immune interactions that are not easily detectable through conventional statistical methods. These systems can be trained to predict autoimmune disease risk, progression trajectories, and therapeutic responses based on microbial and immunological profiles. By integrating clinical, genomic, and microbiome data, AI-driven platforms can support early diagnosis and personalized treatment planning. Such predictive systems represent a critical step toward precision immunology and data-driven healthcare innovation (Chowdhury, 2024b).

8.3. Early-Life Microbiome Modulation for Autoimmune Prevention

Early-life represents a critical developmental window during which the gut microbiome and immune system co-evolve. Disruptions during this period may have long-term consequences for immune tolerance and susceptibility to autoimmune diseases. Evidence suggests that microbial colonization patterns in infancy influence immune system programming, particularly in relation to regulatory T cell development and innate immune training. Therefore, interventions aimed at shaping the early-life microbiome such as dietary modulation, breastfeeding support, and controlled microbial exposure may offer promising preventive strategies against autoimmune diseases. Longitudinal studies in type 1 diabetes have already highlighted the importance of early microbial shifts in disease development, reinforcing the potential of early intervention strategies (Wen et al., 2008).

8.4. Personalized Microbiome Therapeutics

Personalized microbiome-based therapeutics represent a major frontier in autoimmune disease management. Given the high inter-individual variability in microbial composition and immune responses, one-size-fits-all interventions are unlikely to be effective. Instead, future therapies will likely involve individualized microbiome profiling to design targeted interventions, including tailored probiotic formulations, dietary recommendations, and microbiota transplantation strategies. Advances in precision medicine will enable clinicians to match microbial interventions with patient-specific immune profiles, improving therapeutic efficacy and minimizing adverse outcomes. This personalized approach aligns with broader trends in precision immunology and systems medicine.

8.5. Blockchain-Secured Global Microbiome Databases

The rapid expansion of microbiome research necessitates secure, scalable, and interoperable data infrastructures capable of handling sensitive biological and clinical information. Blockchain technology offers a promising solution by providing decentralized, tamper-resistant systems for data storage and sharing. When integrated with cloud-based architectures, blockchain systems can ensure data integrity, transparency, and traceability across global research networks. Such infrastructure is particularly important for microbiome research, where multi-institutional collaboration and large-scale data sharing are essential for advancing discovery. By enabling secure global microbiome databases, blockchain technology can enhance reproducibility, foster collaboration, and support the development of large-scale predictive models in autoimmune disease research (Chowdhury et al., 2024d).



Figure 6 Future Precision Medicine Framework for Microbiome-Driven Autoimmune Therapy

Figure 6 presents a future-oriented precision medicine framework for microbiome-driven autoimmune therapy, integrating advanced biological, computational, and digital health technologies into a unified translational model. The framework begins with multi-omics integration, combining genomics, epigenomics, transcriptomics, proteomics, metabolomics, and microbiomics to generate a comprehensive understanding of host–microbiome interactions and identify predictive biomarkers associated with autoimmune disease risk and progression.

The model further incorporates AI and machine learning prediction systems capable of analyzing complex biological datasets to support disease risk prediction, flare forecasting, treatment-response assessment, and optimal therapeutic timing. Another critical component is early-life microbiome programming, emphasizing the importance of prenatal and childhood microbial exposures, maternal microbiota, nutrition, and environmental factors in shaping long-term immune tolerance and autoimmune susceptibility.

Building on these insights, the framework highlights the development of personalized therapeutics, including precision diets, probiotics, postbiotics, engineered microbial therapies, bacteriophages, and fecal microbiota transplantation (FMT). These interventions are designed to provide individualized treatment strategies based on each patient's microbiome and immunological profile. Supporting this ecosystem is a secure global microbiome data infrastructure powered by blockchain and cloud technologies, enabling decentralized data sharing, interoperability, patient privacy, and large-scale collaborative research.

The figure also illustrates a continuous feedback loop in which real-world clinical data are used to refine predictive models, improve biomarker discovery, and optimize therapeutic interventions over time. Overall, the framework demonstrates how the convergence of microbiome science, artificial intelligence, and secure digital health systems may transform autoimmune disease management into a more predictive, preventive, personalized, and participatory healthcare model.

---

9. Conclusion

The gut microbiota has emerged as a central regulator of immune tolerance, fundamentally reshaping contemporary understanding of autoimmune disease pathogenesis. Evidence synthesized in this review demonstrates that microbial communities influence both innate and adaptive immune systems through multiple interconnected mechanisms, including regulatory T cell induction, short-chain fatty acid signaling, epithelial barrier maintenance, dendritic cell modulation, and mucosal IgA production. Disruption of these tightly regulated processes through dysbiosis contributes to immune imbalance, chronic inflammation, and the development of autoimmune diseases such as rheumatoid arthritis, type 1 diabetes, multiple sclerosis, and inflammatory bowel disease.

Importantly, the gut microbiota functions not merely as a passive microbial community but as a dynamic immunological organ that integrates dietary, environmental, and host genetic signals to maintain immune equilibrium. When this system is perturbed, the resulting breakdown in immune tolerance highlights the microbiome as both a mechanistic driver and a potential therapeutic target in autoimmunity.

Recent advances in microbiome science, combined with emerging technologies such as multi-omics integration, artificial intelligence, and secure data infrastructures, are accelerating the transition from descriptive microbiology to predictive and precision-based immunology. These developments open new possibilities for early diagnosis, individualized therapeutic interventions, and preventive strategies targeting high-risk populations.

Overall, restoring and maintaining gut microbial homeostasis represents a promising frontier in the management of autoimmune diseases. Future research that integrates mechanistic immunology with advanced computational and clinical approaches will be essential to fully translate microbiome-based discoveries into effective and scalable medical interventions.

References

[1] Arpaia, N., Campbell, C., Fan, X., Dikiy, S., van der Veeken, J., deRoos, P., Liu, H., Cross, J. R., Pfeffer, K., Coffer, P. J., & Rudensky, A. Y. (2013). Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. *Nature, 504*(7480), 451–455. https://doi.org/10.1038/nature12726

[2] Atarashi, K., Tanoue, T., Oshima, K., Suda, W., Nagano, Y., Nishikawa, H., Fukuda, S., Saito, T., Narushima, S., Hase, K., Kim, S., Fritz, J. V., Wilmes, P., Umesaki, Y., Itoh, K., & Honda, K. (2013). Treg induction by a rationally selected mixture of *Clostridia* strains from the human microbiota. *Nature, 500*(7461), 232–236. https://doi.org/10.1038/nature12331

[3] Belkaid, Y., & Hand, T. W. (2014). Role of the microbiota in immunity and inflammation. *Cell, 157*(1), 121–141. https://doi.org/10.1016/j.cell.2014.03.011

[4] Brown, E. M., Sadarangani, M., & Finlay, B. B. (2013). The role of the immune system in governing host–microbe interactions in the intestine. *Nature Immunology, 14*(7), 660–667. https://doi.org/10.1038/ni.2611

[5] Burcelin, R., Serino, M., Chabo, C., Blasco-Baque, V., & Amar, J. (2013). Gut microbiota and diabetes: From pathogenesis to therapeutic perspective. *Acta Diabetologica, 50*(2), 257–273. https://doi.org/10.1007/s00592-012-0453-0

[6] Cani, P. D. (2018). Human gut microbiome: Hopes, threats and promises. *Gut, 67*(9), 1716–1725. https://doi.org/10.1136/gutjnl-2018-316723

[7] Chowdhury, R. H. (2024a). Big data analytics in the field of multifaceted analyses: A study on health care management. *World Journal of Advanced Research and Reviews, 22*(03), 2165–2172.

[8] Chowdhury, R. H. (2024b). Harnessing machine learning in business analytics for enhanced decision-making. *World Journal of Advanced Engineering Technology and Sciences, 12*(02), 674–683.

[9] Chowdhury, R. H. (2024c). Intelligent systems for healthcare diagnostics and treatment. *World Journal of Advanced Research and Reviews, 23*(01), 007–015.

[10] Chowdhury, R. H. (2024d). Blockchain and AI: Driving the future of data security and business intelligence. *World Journal of Advanced Research and Reviews, 23*(01), 2559–2570.

[11] Chowdhury, R. H. (2025). Cloud-based data engineering for scalable business analytics solutions: Designing scalable cloud architectures to enhance the efficiency of big data analytics in enterprise settings. *Journal of Technological Science & Engineering, 2*(1), 21–33.

[12] Chowdhury, R. H., Yammanur, V., Touhid, B., & Masum, A. A. (2024). Exploring the integration of blockchain technology in healthcare monitoring systems for enhanced security and data integrity of patient information. *World Journal of Advanced Engineering Technology and Sciences, 13*(02), 297–310.

[13] Cryan, J. F., O'Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M., Codagnone, M. G., Cussotto, S., Fulling, C., Golubeva, A. V., Guzzetta, K. E., Jaggar, M., Long-Smith, C. M., Lyte, J. M., Martin, J. A., Molinero-Perez, A., Moloney, G., Morelli, E., Morillas, E., … Dinan, T. G. (2019). The microbiota–gut–brain axis. *Physiological Reviews, 99*(4), 1877–2013. https://doi.org/10.1152/physrev.00018.2018

[14] Frank, D. N., St. Amand, A. L., Feldman, R. A., Boedeker, E. C., Harpaz, N., & Pace, N. R. (2007). Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. *Proceedings of the National Academy of Sciences, 104*(34), 13780–13785. https://doi.org/10.1073/pnas.0706625104

[15] Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., Takahashi, M., Fukuda, N. N., Murakami, S., Miyauchi, E., Hino, S., Atarashi, K., Onawa, S., Fujimura, Y., Lockett, T., … Ohno, H. (2013). Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. *Nature, 504*(7480), 446–450. https://doi.org/10.1038/nature12721

[16] Honda, K., & Littman, D. R. (2016). The microbiota in adaptive immune homeostasis and disease. *Nature, 535*(7610), 75–84. https://doi.org/10.1038/nature18848

[17] Kamada, N., Seo, S.-U., Chen, G. Y., & Núñez, G. (2013). Role of the gut microbiota in immunity and inflammatory disease. *Nature Reviews Immunology, 13*(5), 321–335. https://doi.org/10.1038/nri3430

[18] Levy, M., Kolodziejczyk, A. A., Thaiss, C. A., & Elinav, E. (2017). Dysbiosis and the immune system. *Nature Reviews Immunology, 17*(4), 219–232. https://doi.org/10.1038/nri.2017.7

[19] Littman, D. R., & Pamer, E. G. (2011). Role of the commensal microbiota in normal and pathogenic host immune responses. *Cell Host & Microbe, 10*(4), 311–323. https://doi.org/10.1016/j.chom.2011.10.004

[20] Macpherson, A. J., & Harris, N. L. (2004). Interactions between commensal intestinal bacteria and the immune system. *Nature Reviews Immunology, 4*(6), 478–485. https://doi.org/10.1038/nri1373

[21] Manasson, J., Shen, N., Garcia Ferrer, H. R., Ubeda, C., Iraheta, I., Heguy, A., Von Feldt, J. M., Espinoza, L. R., Garcia Kutzbach, A., Segal, L. N., & Scher, J. U. (2020). Gut microbiota perturbations in reactive arthritis and postinfectious spondyloarthritis. *Arthritis & Rheumatology, 72*(2), 242–254. https://doi.org/10.1002/art.41040

[22] Peterson, D. A., Frank, D. N., Pace, N. R., & Gordon, J. I. (2008). Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. *Cell Host & Microbe, 3*(6), 417–427. https://doi.org/10.1016/j.chom.2008.05.001

[23] Rooks, M. G., & Garrett, W. S. (2016). Gut microbiota, metabolites and host immunity. *Nature Reviews Immunology, 16*(6), 341–352. https://doi.org/10.1038/nri.2016.42

[24] Scher, J. U., & Abramson, S. B. (2011). The microbiome and rheumatoid arthritis. *Nature Reviews Rheumatology, 7*(10), 569–578. https://doi.org/10.1038/nrrheum.2011.121

[25] Sonnenburg, J. L., & Bäckhed, F. (2016). Diet–microbiota interactions as moderators of human metabolism. *Nature, 535*(7610), 56–64. https://doi.org/10.1038/nature18846

[26] Takiishi, T., Fenero, C. I. M., & Câmara, N. O. S. (2017). Intestinal barrier and gut microbiota: Shaping our immune responses throughout life. *Tissue Barriers, 5*(4), e1373208. https://doi.org/10.1080/21688370.2017.1373208

[27] Tanoue, T., Morita, S., Plichta, D. R., Skelly, A. N., Suda, W., Sugiura, Y., Narushima, S., Vlamakis, H., Motoo, I., Sugita, K., Shiota, A., Takeshita, K., Yasuma-Mitobe, K., Riethmacher, D., Kaisho, T., Norman, J. M., Mucida, D., Suematsu, M., Yaguchi, T., … Honda, K. (2019). A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. *Nature, 565*(7741), 600–605. https://doi.org/10.1038/s41586-019-0878-z

[28] Thaiss, C. A., Zmora, N., Levy, M., & Elinav, E. (2016). The microbiome and innate immunity. *Nature, 535*(7610), 65–74. https://doi.org/10.1038/nature18847

[29] Thaiss, C. A., Levy, M., Grosheva, I., Zheng, D., Soffer, E., Blacher, E., Braverman, S., Tengeler, A. C., Barak, O., Elazar, M., Ben-Zeev, R., Lehavi-Regev, D., Katz, M. N., Pevsner-Fischer, M., Gertler, A., Halpern, Z., & Elinav, E. (2018). Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection. *Science, 359*(6382), 1376–1383. https://doi.org/10.1126/science.aar3318

[30] Vatanen, T., Franzosa, E. A., Schwager, R., Tripathi, S., Arthur, T. D., Vehik, K., Lernmark, Å., Hagopian, W. A., Rewers, M. J., She, J.-X., Toppari, J., Ziegler, A.-G., Akolkar, B., Krischer, J. P., Stewart, C. J., Ajami, N. J., Petrosino, J. F., Gevers, D., Lähdesmäki, H., … Xavier, R. J. (2018). The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. *Nature, 562*(7728), 589–594. https://doi.org/10.1038/s41586-018-0620-2

[31] Wen, L., Ley, R. E., Volchkov, P. Y., Stranges, P. B., Avanesyan, L., Stonebraker, A. C., Hu, C., Wong, F. S., Szot, G. L., Bluestone, J. A., Gordon, J. I., & Chervonsky, A. V. (2008). Innate immunity and intestinal microbiota in the development of Type 1 diabetes. *Nature, 455*(7216), 1109–1113. https://doi.org/10.1038/nature07336

[32] Wu, H.-J., & Wu, E. (2012). The role of gut microbiota in immune homeostasis and autoimmunity. *Gut Microbes, 3*(1), 4–14. https://doi.org/10.4161/gmic.19320

[33] Zhang, X., Zhang, D., Jia, H., Feng, Q., Wang, D., Liang, D., Wu, X., Li, J., Tang, L., Li, Y., Lan, Z., Chen, B., Li, Y., Zhong, H., Xie, H., Jie, Z., Chen, W., Tang, S., Xu, X., … Wang, J. (2015). The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. *Nature Medicine, 21*(8), 895–905. https://doi.org/10.1038/nm.3914

[34] Zhao, L., Zhang, F., Ding, X., Wu, G., Lam, Y. Y., Wang, X., Fu, H., Xue, X., Lu, C., Ma, J., Yu, L., Xu, C., Ren, Z., Xu, Y., Xu, S., Shen, H., Zhu, X., Shi, Y., Shen, Q., & Dong, W. (2018). Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. *Science, 359*(6380), 1151–1156. https://doi.org/10.1126/science.aao5774

[35] Zheng, D., Liwinski, T., & Elinav, E. (2020). Interaction between microbiota and immunity in health and disease. *Cell Research, 30*(6), 492–506. https://doi.org/10.1038/s41422-020-0332-7